Literature DB >> 17453639

A comparison of maximal inspiratory pressure and forced vital capacity as potential criteria for initiating non-invasive ventilation in amyotrophic lateral sclerosis.

Michelle Mendoza1, Deborah F Gelinas, Dan H Moore, Robert G Miller.   

Abstract

Using a retrospective analysis of 161 patients with amyotrophic lateral sclerosis (ALS) from the Western ALS study group (WALS) database, the sensitivity of maximal inspiratory pressure (MIP)< -60 cm H(2)O and forced vital capacity (FVC)< 50% as US Medicare thresholds for initiating non-invasive ventilation (NIV) were compared. Sixty-five per cent of patients at enrollment met the MIP criterion, compared with only 8% of patients who met the FVC criterion. There were no cases in which FVC< 50% antedated MIP< -60 cm H(2)O. The longitudinal data showed that patients reached the MIP criterion 4 to 6.5 months earlier than the FVC criterion. For patients with clinical signs and symptoms needing treatment with NIV, a MIP< -60 cm H(2)O allows US clinicians to obtain non-invasive ventilatory support for patients earlier than if using the FVC criterion alone.

Entities:  

Mesh:

Year:  2007        PMID: 17453639     DOI: 10.1080/17482960601030188

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler        ISSN: 1471-180X


  8 in total

1.  Euthanasia and physician-assisted suicide in amyotrophic lateral sclerosis: a prospective study.

Authors:  Maud Maessen; Jan H Veldink; Bregje D Onwuteaka-Philipsen; Henk T Hendricks; Helenius J Schelhaas; Hepke F Grupstra; Gerrit van der Wal; Leonard H van den Berg
Journal:  J Neurol       Date:  2014-07-15       Impact factor: 4.849

2.  Outcome measures in amyotrophic lateral sclerosis clinical trials.

Authors:  Sabrina Paganoni; Merit Cudkowicz; James D Berry
Journal:  Clin Investig (Lond)       Date:  2014

Review 3.  Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management.

Authors:  David J Birnkrant; Katharine Bushby; Carla M Bann; Benjamin A Alman; Susan D Apkon; Angela Blackwell; Laura E Case; Linda Cripe; Stasia Hadjiyannakis; Aaron K Olson; Daniel W Sheehan; Julie Bolen; David R Weber; Leanne M Ward
Journal:  Lancet Neurol       Date:  2018-02-03       Impact factor: 44.182

4.  A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe disease.

Authors:  Barry J Byrne; Tarekegn Geberhiwot; Bruce A Barshop; Richard Barohn; Derralynn Hughes; Drago Bratkovic; Claude Desnuelle; Pascal Laforet; Eugen Mengel; Mark Roberts; Peter Haroldsen; Kristin Reilley; Kala Jayaram; Ke Yang; Liron Walsh
Journal:  Orphanet J Rare Dis       Date:  2017-08-24       Impact factor: 4.123

Review 5.  Maximum inspiratory pressure as a clinically meaningful trial endpoint for neuromuscular diseases: a comprehensive review of the literature.

Authors:  Benedikt Schoser; Edward Fong; Tarekegn Geberhiwot; Derralynn Hughes; John T Kissel; Shyam C Madathil; David Orlikowski; Michael I Polkey; Mark Roberts; Harm A W M Tiddens; Peter Young
Journal:  Orphanet J Rare Dis       Date:  2017-03-16       Impact factor: 4.123

6.  Associative Increases in Amyotrophic Lateral Sclerosis Survival Duration With Non-invasive Ventilation Initiation and Usage Protocols.

Authors:  Nishad Khamankar; Grant Coan; Barry Weaver; Cassie S Mitchell
Journal:  Front Neurol       Date:  2018-07-12       Impact factor: 4.003

7.  Ultrasonographic modeling of diaphragm function: A novel approach to respiratory assessment.

Authors:  Danielle N O'Hara; Andrey Pavlov; Erin Taub; Sahar Ahmad
Journal:  PLoS One       Date:  2020-03-12       Impact factor: 3.240

8.  Reference Range of Respiratory Muscle Strength and Its Clinical Application in Amyotrophic Lateral Sclerosis: A Single-Center Study.

Authors:  Kee Hong Park; Rock Bum Kim; Jiwon Yang; Jung Hwan Oh; Su Yeon Park; Dong Gun Kim; Je Young Shin; Jung Joon Sung
Journal:  J Clin Neurol       Date:  2016-07       Impact factor: 3.077

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.